Use of lonidamine to potentiate the effect of cisplatin and carboplatin on platinum resistant human ovarian cancer cells

International Journal of Oncology

Volumn 11, Issue 4, 1997, Pages 777-780

  Angioli, Roberto ^a   Janicek, Mike ^a   Sevin, Bernd Uwe ^b   Estape, Ricardo ^a   Averette, Hervy E ^a   Koechli, Ossi R ^c   Untch, Michael ^d   Penalver, Manuel ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Carboplatin; Cisplatin; Lonidamine; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; LONIDAMINE;

ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

EID: 0030886651     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.11.4.777     Document Type: Article

References (24)

1. Lobel TJ, Bardin CW, Gunsalus GL and Musto NA: Effects of lonidamine (AF 1890) and its analogues on follicle stimulating hormone, luteinising hormone, testosterone and rat androgen binding protein concentrations in the rat and rhesus monkey. Chemotherapy 27 (Suppl. 2): 61-72, 1981.
2. Zupi G, Greco C, Laudonio N, Benassi M, Silvestrini B and Caputo A: In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. Anticancer Res 6: 1245-1250, 1986.
3. Bellelli A, Bellelli L, Di Palma M, lorenzon I, Mattioni M, Nista A, Pavese I, Rusconi V and Sezzi ML: Effects of VM-26 and lonidamine on a B16 melanoma cell line. Anticancer Res 10:565-578, 1990.
4. Rosbe KW, Brann TW, Holden SA, Teicher BA and Frei III E: Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother 25: 32-36, 1989.
5. Dogliotti L, Berruti A, Buniva T, Zola P, Baù MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M and Perroni D: Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicentric prospective randomized trial. Clin Oncol 14: 1165-1172, 1996.
6. Kokron O, Maca S, De Gregorio M and Ciottoli GB: Phase II study of lonidamine in non-small cell lung cancer: final report. Br J Cancer 61: 316-318, 1990.
7. Weinerman BH, Eisenhauer EA, Besner J-G, Coppin CM, Stewart D and Band PR: Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada clinical trials group study. Cancer Treatment Rep 70: 751-754, 1986.
8. Ianello GP, De.Cataldis G, Comella P, Della Vittoria Scarpati M, Maiorino A, Brancaccio L, Cioffi R, Lombardi A, Carnicelli P and Tinessa V: Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable non-small cell lung carcinoma. A multicenter randomized clinical trial. Cancer 78: 63-69, 1996.
9. Silvestrini R, Zaffaroni N, Villa R, Orlandi L and Costa A: Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 52: 813-817, 1992.
10. Gadducci A, Brunetti I, Muttini MP, Fanucchi A, Dargenio F, Giannessi PG and Conte PF: Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. Eur J Cancer 30A: 1432-1435, 1944.
11. Floridi A and Lehninger AL: Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascitis tumor mitochondria. Arch Biochem Biophys 226: 73-83, 1983.
12. Hahn GM, Van Kersen I and Silvestrini B: Inhibition of the recovery from potentially lethal damage by lonidamine. Br J Cancer 50: 657-660, 1984.
13. Petru E, Sevin B-U, Perras J, Boike G, Ramos R, Nguyen H and Averette HE: Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence. Gynecol Oncol 38: 155-160, 1990.
14. Nguyen HN, Sevin B-U, Averette HE, Perras J, Ramos R, Angioli R and Ochiai K: Comparison of cytotoxicity and cell kinetic perturbation of five platinum compounds in gynecologic cancer cell lines. Int J Oncol 3: 375-382, 1993.
15. Angioli R, Untch M, Sevin B-U, Steren A, Hightower RD, Perras JP, Nguyen H, Kochli OR and Averette HE: Enhancement of progesterone receptor level by interferons in AE-7 endometrial cancer cells. Cancer 71: 2776-2781, 1993.
16. Angioli R, Sevin B-U, Perras JP, Untch M, Hightower RD, Nguyen HN, Steren A, Schwade JG, Villani C and Averette HE: In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines. Cancer 71: 3717-3725, 1993.
17. Angioli R, Sevin B-U, Untch M, Köchli O, Estape R and Averette HE: Use of interferon and medroxyprogesterone acetate for the treatment of endometrial cancer. Oncol Rep 3: 351-354, 1996.
18. Steren A, Sevin B-U, Perras JP, Angioli R, Nguyen H, Hightower R and Averette HE: Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 48: 252-258, 1993.
19. Untch M, Sevin B-U, Perras J, Angioli R, Babil A, Nguyen H, Hightower R and Averette HE: Chemosensitivity of the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro. Gynecol Oncol 47: 172-178, 1992.
20. Valeriote F and Lin H: Synergistic interaction formula of anticancer agents: a cellular response. Cancer Chemother Rep 59:895-900, 1975.
21. Canetta R, Bragman K, Smaldone L, et al: Carboplatin: current status and future prospects. Cancer Treatment Rev 15: 17-31, 1988.
22. Gershenson DM, Kavanagh JJ, Copeland LJ, et al: Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin based chemotherapy. Obstet Gynecol 73: 798-801, 1989.
23. Ozols RF and Young RC: Chemotherapy of ovarian cancer. Semin Oncol 18:222-232, 1991.
24. Besner JG, Leclaire R, Band PR, Deschamps M, De Sanctis AJ and Catanese B: Pharmacokinetics of lonidamine after oral administration in cancer patients. Oncology 41 (Suppl. 1): 48-52, 1984.